Application of Gastrodia elata Active Ingredients in the Preparation of Drugs for Treating Alzheimer's Disease

Abstract

The present invention belongs to the technical field of Alzheimer's disease drugs, and specifically relates to the application of gastrodia active ingredients in the preparation of drugs for treating Alzheimer's disease. The gastrodia active ingredients are gastrodin and gastrodia polysaccharide, which are compounded with known therapeutic preparations for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodia polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50-100:150-200:2-3. The present invention clarifies the use of gastrodia active ingredients in the preparation of drugs for treating Alzheimer's disease.

Description

Technical Field

[0001] The present invention belongs to the technical field of Alzheimer's disease drugs, and particularly relates to the application of active components of Gastrodia elata in the preparation of drugs for treating Alzheimer's disease. Background Art

[0002] Alzheimer's disease, also known as senile dementia, mostly occurs in old age and belongs to the disorder of higher nervous function activities. The main clinical manifestations are memory disorders, thinking disorders, visual-spatial recognition disorders, and emotional disorders. The causes of Alzheimer's disease are complex, so many drugs in the prior art can only improve the related clinical symptoms and slow down the aggravation of the disease. Patients usually need to take medicine for a long time.

[0003] Traditional Chinese medicine is considered to be a drug with relatively high safety, suitable for long-term use, with small side effects or even no side effects. Therefore, there are many traditional Chinese medicines for treating Alzheimer's disease in the prior art, such as Xuefu Zhuyu Decoction (the main components include Angelica sinensis, Ligusticum wallichii, Rehmannia glutinosa, Prunus persica, Carthamus tinctorius, Fructus aurantii, Paeonia lactiflora, Bupleurum chinense, Cyathula officinalis, Panax notoginseng, Pheretima aspergillum, and Glycyrrhiza uralensis Fisch.), Tianma Gouteng Decoction (Gastrodia elata, Uncaria rhynchophylla, Concha haliotidis, Gardenia jasminoides Ellis, Eucommia ulmoides Oliv., Pueraria lobata (Willd.) Ohwi, Taxillus chinensis (DC.) Danser, Cyathula officinalis Kuan, Chrysanthemum morifolium Ramat., Vitex trifolia L. var. simplicifolia Cham., Lycium barbarum L., and Glycyrrhiza uralensis Fisch.), etc. However, these prescriptions contain many kinds of Chinese medicinal materials and even more active components, and it is not clear which specific active components play a role in treating Alzheimer's disease. Summary of the Invention

[0004] In order to solve the above technical problems, the present invention provides the application of active components of Gastrodia elata in the preparation of drugs for treating Alzheimer's disease.

[0005] The purpose of the present invention is to provide the application of active components of Gastrodia elata in the preparation of drugs for treating Alzheimer's disease. The active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide, and the known therapeutic preparation for treating Alzheimer's disease is 50-100:150-200:2-3.

[0006] Both gastrodin and gastrodian polysaccharide are known active components of Gastrodia elata, and many related products can also be purchased on the market. For example, the gastrodian polysaccharide used in the experiments of the present invention was purchased from Yangling Ciyuan Biotechnology Co., Ltd., with an active ingredient content of 95%; the gastrodin was purchased from Xi'an Youshuo Biotechnology Co., Ltd., with an active ingredient content of 98%, white powder, 80 mesh.

[0007] Prior art research shows that although gastrodin is a neuroprotective agent, it has no therapeutic effect on Alzheimer's disease. Gastrodia polysaccharide is often used for antioxidant, anti-tumor, liver protection and immune enhancement, and there is no treatment for Alzheimer's disease either. However, considering that these two substances are the active ingredients of Gastrodia elata and have high safety, we compound them with known drugs for the treatment of Alzheimer's disease to enhance the drug effect. The present invention discovers for the first time that gastrodin and gastrodia polysaccharide can be used to prepare drugs for the treatment of Alzheimer's disease.

[0008] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the known therapeutic agents for Alzheimer's disease are acetylcholinesterase inhibitors, N-methyl-D-aspartic acid receptor antagonists or cerebral metabolic activators, mainly to improve cognitive function. For example, the known therapeutic agents for Alzheimer's disease use donepezil hydrochloride, rivastigmine tartrate, memantine hydrochloride, or oxiracetam, such as the corresponding existing technology drug names are donepezil hydrochloride tablets, rivastigmine tartrate capsules, memantine hydrochloride sustained-release capsules or oxiracetam capsules.

[0009] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the drug for Alzheimer's disease is an oral preparation.

[0010] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the oral preparation is a capsule or a tablet, which is composed of gastrodin, gastrodia polysaccharide, known therapeutic agents for Alzheimer's disease and a first excipient.

[0011] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the first excipient is one or more of starch, alumina and calcium stearate.

[0012] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, gastrodin and gastrodia polysaccharide are first made into an oral preparation with a second excipient, and then compounded with known therapeutic agents for Alzheimer's disease.

[0013] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the second excipient is one or several of starch, methylcellulose, dextrin, alumina, magnesium stearate and calcium stearate.

[0014] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the subjects suffering from Alzheimer's disease are naturally diseased humans, mice or constructed Alzheimer's disease animal models.

[0015] Preferably, in the application of the above-mentioned active ingredients of Gastrodia elata in the preparation of drugs for the treatment of Alzheimer's disease, the drug for the treatment of Alzheimer's disease is used to reduce the activity of acetylcholinesterase.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The present invention provides an application of gastrodia active ingredients in the preparation of drugs for treating Alzheimer's disease, which has good safety and efficacy. The gastrodia active ingredients are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50-100:150-200:2-3. The present invention develops a new use of gastrodin and gastrodian polysaccharide for reducing the activity of acetylcholinesterase and treating Alzheimer's disease, thereby providing an application of gastrodia active ingredients in the preparation of drugs for treating Alzheimer's disease.

[0018] In the experiments of the present invention, compounding a known drug for treating Alzheimer's disease with gastrodin and / or gastrodian polysaccharide can significantly reduce acetylcholinesterase and improve Alzheimer's disease. Moreover, the research results of the present invention show that gastrodin and gastrodian polysaccharide have the effect of reducing acetylcholinesterase, and after compounding with a known drug for treating Alzheimer's disease, the effect of improving Alzheimer's disease is better. Description of the Drawings

[0019] Figure 1 It is the statistical result of the residence time in the central grid.

[0020] Figure 2 It is the statistical result of the standing times.

[0021] Figure 3 It is the statistical result of the total walking distance.

[0022] Figure 4 It is the recorded result of the escape latency.

[0023] Figure 5 It is the swimming distance.

[0024] Figure 6 It is the swimming speed.

[0025] Figure 7 It is the statistical result of the acetylcholinesterase activity. Detailed Embodiments

[0026] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention will be further described below with reference to specific embodiments and the drawings.

[0027] In the description of the present invention, unless otherwise specified, the reagents used are commercially available, and the methods used are conventional techniques in the art.

[0028] The structural formula of gastrodin is shown in formula (1), and the molecular formula is C 13 H18 O7, with the CAS number 62499-27-8. In the prior art, drugs containing gastrodin as a component include acetyl gastrodin tablets, which are used for insomnia, neurasthenia, vascular headache, and neural headache, etc.; gastrodin injection, mainly used in the department of neurology, can be used to treat dizziness, such as dizziness caused by hypofunction of the vestibular nerve, Meniere's syndrome, and vertebrobasilar artery insufficiency. Prior art research shows that although gastrodin is a neuroprotective agent, it has no therapeutic effect on Alzheimer's disease.

[0029]

[0030] The common components in gastrodia elata polysaccharide are L-rhamnose, L-fucose, D-xylose, D-mannose, and D-glucose. Existing research shows that gastrodia elata polysaccharide has various biological activities, such as antioxidant, scavenging free radicals in the body, delaying aging, and improving immunity. These biological activities make gastrodia elata polysaccharide have broad application prospects in the fields of medicine and health care. However, it is not shown in the prior art that gastrodia elata polysaccharide has no therapeutic effect on Alzheimer's disease.

[0031] For newly prepared compound drugs, they need to go through various tests such as molecular formula design, structural formula design, animal experiments, clinical trials, and safety tests. The process is very complex, and the labor cost, time cost, and economic cost consumed are very high. In contrast, developing new indications for known drugs requires less testing, saves costs and resources, and is an energy-saving and environmental-friendly practice. In the prior art, researchers have published many patents or papers related to the discovery of new indications, such as CN200610104629.6, CN200810041513.1, "Li Ni. Development of New Indications of Drugs - Efficacy Evaluation and Mechanism Research of Anti-Enterovirus EV71 [D]. Hubei University of Technology [2024-10-11]", etc.

[0032] Both gastrodin and gastrodia elata polysaccharide are known active components of gastrodia elata, with clear components and high safety, and are suitable for long-term use. Therefore, it is necessary to continue to develop their new uses. In addition, there are many traditional Chinese medicines for treating Alzheimer's disease in the prior art, which are compounded with multiple medicinal materials and contain more active components. It is not clear which specific active components play a role in treating Alzheimer's disease, and there are safety risks.

[0033] For the above reasons, the present invention provides an application of active components of gastrodia elata in the preparation of drugs for treating Alzheimer's disease. The active components of gastrodia elata are gastrodin and gastrodia elata polysaccharide, and the two are compounded with a known therapeutic preparation for Alzheimer's disease. The mass ratio of gastrodin, gastrodia elata polysaccharide, and the known therapeutic preparation for Alzheimer's disease is 50-100:150-200:2-3.

[0034] Example 1

[0035] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to form a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50:150:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride.

[0036] Example 2

[0037] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to form a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 80:150:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride.

[0038] Example 3

[0039] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to form a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 100:150:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride.

[0040] Example 4

[0041] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to form a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50:170:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride.

[0042] Example 5

[0043] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to form a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50:200:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride.

[0044] Example 6

[0045] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to prepare a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50:150:3. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride.

[0046] Example 7

[0047] A drug for treating Alzheimer's disease, wherein the active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for treating Alzheimer's disease to prepare a drug for treating Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 50:150:2. The known therapeutic preparation for treating Alzheimer's disease is memantine hydrochloride.

[0048] Control 1

[0049] A drug for treating Alzheimer's disease, wherein the active component of Gastrodia elata is gastrodin. The active component of Gastrodia elata is compounded with a known therapeutic preparation for treating Alzheimer's disease to prepare a drug for treating Alzheimer's disease. The mass ratio of gastrodin and the known therapeutic preparation for treating Alzheimer's disease is 200:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride. That is, compared with Example 1, an equal mass of gastrodin is used to replace gastrodian polysaccharide.

[0050] Control 2

[0051] A drug for treating Alzheimer's disease, wherein the active component of Gastrodia elata is gastrodian polysaccharide. The active component of Gastrodia elata is compounded with a known therapeutic preparation for treating Alzheimer's disease to prepare a drug for treating Alzheimer's disease. The mass ratio of gastrodian polysaccharide and the known therapeutic preparation for treating Alzheimer's disease is 200:2. The known therapeutic preparation for treating Alzheimer's disease is donepezil hydrochloride. That is, compared with Example 1, an equal mass of gastrodian polysaccharide is used to replace gastrodin.

[0052] Control 3

[0053] A drug for treating Alzheimer's disease, wherein the active component of Gastrodia elata is a mixture of gastrodin and gastrodian polysaccharide, and the mass ratio of gastrodin to gastrodian polysaccharide is 50:150. That is, compared with Example 1, the known therapeutic preparation for treating Alzheimer's disease is removed.

[0054] Control 4

[0055] A drug for treating Alzheimer's disease is gastrodin.

[0056] Control 5

[0057] A drug for treating Alzheimer's disease is gastrodian polysaccharide.

[0058] The present invention provides an application of the active ingredients of Gastrodia elata in the preparation of drugs for treating Alzheimer's disease, and the relevant experimental results are as follows.

[0059] I. Experimental animals

[0060] Healthy 6-week-old C57 female mice were selected and adaptively fed for 4 days. On the 5th day, Aβ was injected into the brain. 25-35 , Aβ 25-35 with a concentration of 35 pmol / μL, and 5 μL was injected into the brain of each C57 female mouse to establish an animal model of Alzheimer's disease.

[0061] Among them, the method of brain injection is as follows:

[0062] (1) The C57 female mice were anesthetized by intraperitoneal injection of sodium pentobarbital with a mass fraction of 0.4%, 0.2 mL / 10 g body weight, and then fixed on a stereotaxic apparatus.

[0063] (2) The scalp was incised longitudinally, and the coordinates for bilateral ventricular catheterization were 0.8 mm anterior to the bregma, 1.1 mm lateral to the midline, and 3.6 mm below the dura mater.

[0064] (3) 5 μL of freshly prepared 35 pmol / μL Aβ 25-35 was slowly injected into one lateral ventricle respectively, with a total of 5 μL in the whole brain. The injection rate was about 1 μL / min, and the interval between each injection was 2 hours.

[0065] (4) After leaving the needle for 2 minutes, the tube was removed, and the skull hole was sealed with bone wax and the incision was sutured.

[0066] II. Drug administration and modeling treatment

[0067] Model group: Starting from the 6th day, 100 μL of 0.9 wt% normal saline was administered by gavage every day.

[0068] Example 1 group: Starting from the 6th day, 100 μL of the medicinal liquid prepared from the drug of Example 1 was administered by gavage every day. Calculated by donepezil hydrochloride, 2 μg of donepezil hydrochloride was contained in 100 μL of the medicinal liquid.

[0069] Example 2 group: Starting from the 6th day, 100 μL of the medicinal liquid prepared from the drug of Example 2 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the medicinal liquid contained the same amount of the drug as in the Example 1 group.

[0070] Example 3 group: Starting from the 6th day, 100 μL of the medicinal liquid prepared from the drug of Example 3 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the medicinal liquid contained the same amount of the drug as in the Example 1 group.

[0071] Example 4 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Example 4 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0072] Example 5 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Example 5 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0073] Example 6 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Example 6 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0074] Example 7 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Example 7 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0075] Control 1 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Control 1 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0076] Control 2 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Control 2 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0077] Control 3 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Control 3 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0078] Control 4 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Control 4 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0079] Control 5 group: Starting from the 6th day, 100 μL of the liquid medicine prepared from the drug of Control 5 was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0080] Control 6 group: Starting from the 6th day, 100 μL of the suspension prepared from donepezil hydrochloride was administered by gavage every day. Calculated by the total mass of the drug, 100 μL of the liquid medicine contained the same amount of drug as that in the Example 1 group.

[0081] Blank control: Healthy female C57 mice.

[0082] In the present invention, the model group is used to reflect the condition of untreated C57 female mice, the blank control is used to reflect the condition of healthy C57 female mice, and the groups of Example 1 to Example 7 are used to reflect the therapeutic effects of the corresponding drugs in Example 1 to Example 7 for treating Alzheimer's disease. Control Group 1 is used to reflect the therapeutic effect of the compounding of gastrodin and a known therapeutic preparation for treating Alzheimer's disease, Control Group 2 is used to reflect the therapeutic effect of the compounding of gastrodian polysaccharide and a therapeutic preparation for treating Alzheimer's disease, and Control Group 3 is used to reflect the therapeutic effect of the compounding of gastrodin and gastrodian polysaccharide. Control Group 4 is used to reflect the therapeutic effect of gastrodin alone. Control Group 5 is used to reflect the therapeutic effect of gastrodian polysaccharide alone. Control Group 6 is used to reflect the therapeutic effect of a known drug for treating Alzheimer's disease.

[0083] Continuous treatment was carried out for 7 days. On the 8th day, an open field test and a Morris water maze test were conducted to measure the acetylcholinesterase activity.

[0084] III. Data processing method

[0085] Three parallel tests were carried out for each group, and the results were averaged for significant analysis.

[0086] IV. Open field test and results

[0087] The residence time, standing times, and total walking distance of female mice in each group in the central square were observed, and the results were averaged (n = 6). The results are as Figures 1 to 3 shown. Specifically, Figure 1 is the statistical result of the residence time in the central square. Figure 2 is the statistical result of the standing times. Figure 3 is the statistical result of the total walking distance.

[0088] From Figure 1 it can be seen that compared with the blank control, the female mice in the model group had a significantly prolonged residence time in the central square, P < 0.05; significantly reduced standing times, P < 0.05; and significantly shortened total walking distance, P < 0.05. Compared with the model group, the residence time in the central square of each example group was significantly shortened, P < 0.05, and the standing times and total walking distance were significantly increased, P < 0.05. The comparison results with the blank control group and the model group showed that the drugs for treating Alzheimer's disease provided in the embodiments of the present invention could effectively relieve Alzheimer's disease.

[0089] Control Group 1 is the compounding of gastrodin and a known therapeutic preparation for treating Alzheimer's disease, and Control Group 2 is the compounding of gastrodian polysaccharide and a therapeutic preparation for treating Alzheimer's disease. After comparison with the model group and the blank control, it was shown that they also had a certain effect of relieving Alzheimer's disease, but there were still significant differences from the drugs of each example of the present application.

[0090] Control Group 3 is the compound of gastrodin and gastrodian polysaccharide. Control Group 4 is gastrodin alone. Control Group 5 is gastrodian polysaccharide alone. Control Group 6 is a known drug for treating Alzheimer's disease. The results show that when gastrodin and gastrodian polysaccharide are used alone, the effect of treating Alzheimer's disease is almost nil; when gastrodin and gastrodian polysaccharide are compounded, there is a certain therapeutic effect, indicating that there is a mutual enhancement effect when the two are compounded. When one or both of gastrodin and gastrodian polysaccharide are combined with a known drug for treating Alzheimer's disease, the therapeutic effect is better than using the known drug for treating Alzheimer's disease alone, indicating that one or both of gastrodin and gastrodian polysaccharide can enhance the efficacy of the known drug for treating Alzheimer's disease.

[0091] V. Morris water maze experiment and results

[0092] ① Place the platform 0.5 cm below the water surface. Female mice enter the water facing the pool wall from the middle position of the four quadrants of the platform respectively, and record the escape latency, that is, the time when the female mouse finds the platform and stays for 20 s.

[0093] After continuous training for five days, conduct the above experiment again and record the escape latency. The results are averaged (n = 6).

[0094] The results are shown in Figure 4 . Compared with the blank control, the escape latency of female mice in the model group was significantly prolonged, P < 0.05. Compared with the model group, the escape latency in each example group was significantly shortened, P < 0.05.

[0095] ② On the sixth day of the experiment, remove the platform, and the other conditions are the same as in ①. Record the swimming distance and speed of the female mice within 90 s.

[0096] The results are shown in Figures 5 to 6 . Specifically, Figure 5 is the swimming distance, Figure 6 is the swimming speed.

[0097] The results of the Morris water maze experiment were consistent with those of the open field experiment. That is, compared with the blank control group and the model group, the drug for treating Alzheimer's disease provided by the embodiments of the present invention could effectively alleviate Alzheimer's disease. When gastrodin was compounded with a known therapeutic preparation for treating Alzheimer's disease, and when gastrodian polysaccharide was compounded with a therapeutic preparation for treating Alzheimer's disease, after comparison with the model group and the blank control, it was shown that they also had a certain effect of alleviating Alzheimer's disease, but there were still significant differences from the drugs of each embodiment of the present application. When gastrodin and gastrodian polysaccharide were used alone, the effect of treating Alzheimer's disease was almost negligible; when gastrodin and gastrodian polysaccharide were compounded, they had a certain therapeutic effect, indicating that there was a mutual enhancement effect between the two. When one or both of gastrodin and gastrodian polysaccharide were compounded with a known drug for treating Alzheimer's disease, the therapeutic effect was better than using the known drug for treating Alzheimer's disease alone, indicating that one or both of gastrodin and gastrodian polysaccharide could enhance the efficacy of the known drug for treating Alzheimer's disease.

[0098] V. Test Results of Acetylcholinesterase Activity

[0099] Most Alzheimer's disease patients have abnormal acetylcholinesterase activity, and acetylcholinesterase is also often used as one of the diagnostic and treatment judgment indicators for Alzheimer's disease patients. Therefore, the present invention tested the acetylcholinesterase activity of female mice participating in the experiment to evaluate the efficacy of each group of drugs.

[0100] The results are shown in Figure 7 . The acetylcholinesterase activity of the model group was significantly higher than that of each embodiment group of the present invention. The acetylcholinesterase activity of the blank control was the lowest. Gastrodin and gastrodian polysaccharide had the effect of reducing acetylcholinesterase activity, and when one or both of gastrodin and gastrodian polysaccharide were compounded with a known drug for treating Alzheimer's disease, the effect of reducing acetylcholinesterase activity was more obvious.

[0101] In summary, in the experiments of the present invention, compounding a known drug for treating Alzheimer's disease with gastrodin and / or gastrodian polysaccharide could significantly reduce acetylcholinesterase activity and improve Alzheimer's disease. And the research results of the present invention show that gastrodin and gastrodian polysaccharide have the effect of reducing acetylcholinesterase activity, and after compounding with a known drug for treating Alzheimer's disease, the effect of improving Alzheimer's disease is better.

[0102] It should be noted that when the present invention involves a numerical range, it should be understood that both endpoints of each numerical range and any value between the two endpoints can be selected. Since the adopted step method is the same as that of the embodiment, in order to prevent redundancy, the present invention describes the preferred embodiments. Although the preferred embodiments of the present invention have been described, once those skilled in the art know the basic inventive concept, additional changes and modifications can be made to these embodiments, and these changes and modifications all fall within the scope of the present invention.

[0103] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. If these modifications and variations of the present invention fall within the scope of the equivalent technology of the present invention, the present invention also intends to include these changes and deformations.

Claims

1. Use of active ingredients of Gastrodia elata in the preparation of a medicament for treating Alzheimer's disease, characterized in that, The active components of Gastrodia elata are gastrodin and gastrodian polysaccharide, and the two are compounded with a known therapeutic preparation for Alzheimer's disease. The mass ratio of gastrodin, gastrodian polysaccharide and the known therapeutic preparation for Alzheimer's disease is 50-100:150-200:2-3; The known therapeutic preparation for Alzheimer's disease is donepezil hydrochloride or memantine hydrochloride.

2. Use of the active ingredient of Gastrodia elata Blume in the preparation of a medicament for treating Alzheimer's disease, characterized in that, The drug for treating Alzheimer's disease is an oral preparation.

3. Use of the active ingredients of Gastrodia elata Blume according to claim 2 in the preparation of a medicament for treating Alzheimer's disease, characterized in that, The oral preparation is a capsule or a tablet, and is made of gastrodin, gastrodian polysaccharide, a known therapeutic preparation for Alzheimer's disease and a first auxiliary material.

4. Use of the active ingredients of Gastrodia elata Blume according to claim 3 in the preparation of a medicament for treating Alzheimer's disease, characterized in that, The first auxiliary material is one or more of starch, aluminum oxide and calcium stearate.

5. Use of the active ingredient of Gastrodia elata Blume in the preparation of a medicament for treating Alzheimer's disease, characterized in that, First, gastrodin and gastrodian polysaccharide are made into an oral preparation with a second auxiliary material, and then compounded with a known therapeutic preparation for Alzheimer's disease.

6. Use of the active ingredient of Gastrodia elata Blume in the preparation of a medicament for treating Alzheimer's disease, characterized in that, The second auxiliary material is one or several of starch, methylcellulose, dextrin, aluminum oxide, magnesium stearate and calcium stearate.

7. Use of the active ingredients of Gastrodia elata Blume as claimed in claim 1 in the preparation of a medicament for treating Alzheimer's disease, characterized in that, The subjects suffering from Alzheimer's disease are naturally diseased humans, mice or constructed Alzheimer's disease animal models.

Images